Most Recent Articles by Noah Pines
A relative's illness challenges a pharma consultant's view of industry progress.
With some of the biggest patent expiries due to pass in 2013, the next two years will be important in terms of pharma's return to growth, says Sanford Bernstein's Dr. Tim Anderson in a discussion with Noah Pines
Abbott and BMS peeled back the curtain on some impressive clinical trial results, suggesting that Gilead may have some competition in the sprint for an all-oral anti-HCV treatment.
The deadly meningitis outbreak highlights the threat not only to public health, but also to the pharma industry, posed by the largely unregulated practice of pharmacy compounding.
Boehringer Ingelheim has long been associated with treatments for stroke prevention, COPD and HIV/AIDS, but not cancer. That's about to change, if a cornucopia of 13 abstracts presented at the European Society for Medical Oncology (ESMO) is any evidence.
More Articles by Noah Pines
- Five things for pharma marketers to know: Friday, February 5, 2016
- Why Gathering Health Economic Data for Cancer Drugs is Now Essential
- Ascension Health ups Ragone to chief marcomms officer
- House Oversight committee upbraids Turing, Valeant execs
- Burcin departs Havas network for Klick Health in senior-staffing push